Apellis Pharmaceuticals Inc (NAS:APLS)
$ 39.68 -3.92 (-8.99%) Market Cap: 4.82 Bil Enterprise Value: 5.07 Bil PE Ratio: 0 PB Ratio: 18.04 GF Score: 38/100

Apellis Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 14, 2020 / 11:30PM GMT
Release Date Price: $41.85 (+3.74%)
Anupam Rama
JP Morgan Chase & Co, Research Division - VP and Analyst

All right. We'll go ahead and get started. So welcome to the Tuesday afternoon session of the 2020 JPMorgan Healthcare Conference. My name is Anupam Rama. I am joined by Matt Bannon, Tessa Romero and Julie Murphy from the team. Our next presenting company is Apellis, and presenting on behalf of the company is Cedric Francois. Cedric?

Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director

Thank you very much, Anupam, and thank you for inviting us for the third year in a row, and all the hard work that you and the team do for us. And thank you all of you for attending. This is a special JPMorgan for us where we are presenting to you the data from our PEGASUS study in paroxysmal nocturnal hemoglobinuria. And we are going to start with this slide, where of course, today, a lot of time will be spent on those positive data in our Phase III clinical trial, but also on the platform that we believe we are unlocking around this fascinating target of complement

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot